Pharmacyte Biotech Inc (OTCMKTS:PMCB) Presents at Conference

Pharmacyte Biotech Inc (OTCMKTS:PMCB)

Pharmacyte Biotech Inc (OTCMKTS:PMCB), based in Laguna Hills, CA, announced that its Chief Executive Officer, Kenneth L. Waggoner, will present PharmaCyte’s therapy for pancreatic cancer at the 2017 BIO International Convention (BIO). BIO is to be held June 17-22, 2017 in San Diego, California at the San Diego Convention Center. This year’s theme is “Breakthrough,” which is designed to highlight the breakthrough leadership, technology and science that happens every day in the biotechnology industry.

Pharmacyte Biotech Inc (OTCMKTS:PMCB) uses proprietary cellulose-based live cell encapsulation technology to develop treatments for cancer and diabetes. Their proprietary technology is commonly known as “Cell-in-a-Box” and involves encapsulating genetically engineered cells that convert the prodrug ifosfamide from its naturally inactive form into a “cancer killing” form. The encapsulated live cells are then implanted, as close as possible, to the cancerous cells. When the ifosfamide comes in contact with the encapsulated live cells, they act as an artificial liver and activate the ifosfamide at the source of the cancer. For diabetes, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. Pharmacyte Biotech Inc (OTCMKTS:PMCB) plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body.

From April 30, 2016 to January 31, 2017 Pharmacyte Biotech Inc (OTCMKTS:PMCB) increased its total assets bringing that line item to $7.6 million. During that same time period, liabilities decreased from $637,639 to $578,267. At the end of January, 2017, total stockholder equity was listed at just over $7 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PMCB and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Anavex Life Sciences Corp (OTCMKTS:AVXL) Down Again

Anavex Life Sciences Corp (OTCMKTS:AVXL)

Anavex Life Sciences Corp (OTCMKTS:AVXL) is a clinical stage biotechnology firm headquartered in New York City. Anavex develops therapies for the treatment of neurodegenerative and neurodevelopmental diseases such as Alzheimers, Parkinson’s, and Rett Syndrome. On Kune 9th, Anavex’s CEO, Dr. Chris Missling, presented at the renowned Jeffries 2017 Global Healthcare Conference in New York City. Typically such presentations serve as a boost to a biotech’s share price – however AVXL has dropped slightly since that presentation.

The lead product candidate from Anavex Life Sciences Corp (OTCMKTS:AVXL) is Anavex 2-73 for the indications of Alzheimer’s, cognition in neuropsychiatric epilepsy, Parkinson’s, Multiple Sclerosis, and Rett Syndrome. Anavex 2-73 just completed a Phase 2a Clinical trial and while reported results were positive, they were not without critics. Anavex 2-73 reportedly stabilized Alzheimer’s disease for a period of one year, becoming the first drug to accomplish the milestone. However some observers believe the trials were too small and, therefore, the results should not have the same level of confidence attached to them despite the meeting of stated endpoints. Anavex Life Sciences Corp (OTCMKTS:AVXL) also has two drug candidates that have completed their preclinical trials for three indications – Parkinson’s, Depression, and Stroke. Five other durg candidates are in preclinical trials for indications of varying types of cancer.

In late 2015, shares of Anavex Life Sciences Corp (OTCMKTS:AVXL) were briefly trading around $15. Since March AVXL shares have been in a relatively tight trading range between $5.60 and $6.30. However support at the $5.60 level disappeared last week as each day saw successively lower lows which ended with AVXL closing at $5.36 after hitting lows of $5.10. AVXL is slightly down in early morning trading today.

Anavex Life Sciences Corp (OTCMKTS:AVXL) shareholders have historically been diluted at high levels. In 2012, there were 7.04 million shares outstanding and by 2016 there were over 35.15 million shares outstanding. More recently, share performance has been positive. YTD AVXL shares are up over 35% and up almost 25% for the year. While AVXL has a $15 price target, short-sellers still represent over 14% of the stock’s float, which likely indicates a lack of strong positive sentiment for the stock.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AVXL and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Lotus Bio-Technology Development Corp (OTCMKTS:LBTD)

Lotus Bio-Technology Development Corp (OTCMKTS:LBTD)

Lotus Bio-Technology Development Corp (OTCMKTS:LBTD) is a unique biotechnology firm located in Cave Creek, AZ with a branch in the agricultural fields of China. On Friday, its shares exploded and ended the day at $0.19 – over 110% higher than they closed on Thursday. Volumes were over ten times their 30-day, daily average trading volume as over 130,000 shares traded.

Lotus Bio-Technology Development Corp (OTCMKTS:LBTD) organically cultivates plants and extracts material from them for use in the manufacture of every day consumer goods – such as soap. Lotus has recently leased several hundred acres of farmland in China for a period of 30 years.

Lotus Bio-Technology Development Corp (OTCMKTS:LBTD) will grow organic food, Camellia Oleifera, and traditional Chinese medicine (herbs) to maximize the farmland’s utilization. Camellia Oleifera is an important source of edible oil and its seeds are processed to yield tea oil, a common ingredient in Chinese medicine and cosmetics. Camellia seed oil reportedly also has weight-loss properties and a high level of anti-oxidants. There is a large demand for Camellia oil and the products that can be processed from it and the price of tea oil has increased from $5,000 per ton to $10,000 per ton in recent years.

In May, the company appointed a new Chief Executive Officer, Michael Palethorpe. Mr. Palethorpe has founded several successful companies since 1998, including one that became a global leader in XML technologies. Mr. Palethorpe also launched the world’s second largest mountain bike website, boasting over 20,000 unique daily users. Michael managed a sales team that produced over $1,000,000 in annual revenues for Metasoft Systems, Inc. He most recently spent 6 years running a private marketing Company, followed by a 3-year tenure as President and CEO of New Media Insight Group.

Adding to the Lotus Bio-Technology Development Corp (OTCMKTS:LBTD)’s interesting business profile, a quick review of the company’s financials shows that no revenues have been generated and assets are listed at just $5,000 while liabilities are over $60,000.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $LBTD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Can Downsizing Save ENUMERAL BIOMEDICA COM USD0.001 (OTCMKTS:ENUM)

ENUMERAL BIOMEDICA COM USD0.001 (OTCMKTS:ENUM)

ENUMERAL BIOMEDICA COM USD0.001 (OTCMKTS:ENUM) volumes exploded last Friday. Shares of the biotech company have a 30-day, daily average trading volume figure of 43,152. However by the close of trading last Friday over 237,000 shares had traded hands. Remarkably, the share price for ENUM was down just 4.76% although the closing price of $0.08 was the low of the day. Interestingly, the two largest trading volumes over the past month have accompanied down moves in the stock.

Cambridge, MA-based ENUMERAL BIOMEDICA COM USD0.001 (OTCMKTS:ENUM) discovers and develops antibody immunotherapies that assist the body’s immune system attack diseased cells. Their process allows them to measure drugs in a customizable fashion for each patient. Enumeral is building a pipeline of treatments for cancer and inflammatory diseases.

On June 9, 2017 ENUMERAL BIOMEDICA COM USD0.001 (OTCMKTS:ENUM) filed a form with the SEC detailing their separation from the company’s former CEO Dr. Arthur Tinkelenberg. Also included in the form was the assertion that the company has implemented a reduction in the company’s labor force. This course of action is being taken to prolong the company’s ability to operate. Currently Enumeral believes they have enough cash to operate through June, 2017. However the SEC filing makes it clear that avenues are being investigated to avoid having the company be forced to wind down. These options could include a sale, private debt or equity offerings, collaborations, licensing, or even a merger – among other possibilities.

Investors would be well advised to keep a close eye on any news concerning ENUMERAL BIOMEDICA COM USD0.001 (OTCMKTS:ENUM).

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ENUM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Arch Therapeutics Inc (OTCMKTS:ARTH) Awaits FDA Decision

Arch Therapeutics Inc (OTCMKTS:ARTH)

Ironically, Arch Therapeutics Inc (OTCMKTS:ARTH) was trading below $0.50 a year ago before the biotech stock went north and hit a 52-week high of $0.78. Still, the medical device company is trading around double what it was trading at in early 2016. The company’s success in the market tracked the success of its AC5 surgical hemostatic device. Hemostasis is a process that causes bleeding to stop.

Arch Therapeutics Inc (OTCMKTS:ARTH) is based out of Wellesley, MA and develops surgical care products designed to stop bleeding and control leaking – amongst other benefits. AC5 is their lead product candidate and is applied directly into wounds through a spray or liquid squirt. AC5 is designed to invade the nooks and crannies of the connective tissue and build into a physical structure that ceases bleeding or the leakage of other bodily fluids. Needless to say, the market is enormous for a liquid medical product that can stop bleeding effectively.

Earlier this year, Arch Therapeutics Inc (OTCMKTS:ARTH) had a registered direct offering for over 10.1 million units. Each unit consisted of one shares of ARTH and a 0.55 of a Series F Warrant that is exercisable at $0.75 per ARTH share and have a term of five years. Each unit was sold at $0.60 and total gross proceeds are expected to be in the range around $6.1 million and around $825,000 of that total will be used to retire some debt. The company expects the raised cash to be able to fulfill operational expense demands into the 3rd quarter of 2018.

More recently, Arch Therapeutics Inc (OTCMKTS:ARTH) announced their intention to file for a 510(k) allowance with the U.S. Food and Drug Administration (FDA). Terrence Norchi, CEO of Arch Therapeutics Inc (OTCMKTS:ARTH), stated in the press release that significant benefits will come to the firm in the form of business opportunities and technological validation if the 501(k) is approved. Approval would also mean a shorter time to market for AC5. As of now, Arch Therapeutics Inc (OTCMKTS:ARTH) expects AC5 to be commercialized sometime in 2018.

YTD, Arch Therapeutics Inc (OTCMKTS:ARTH) has lost over 20% while the S&P 500 has gained around 8%.

 I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ARTH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

 

Theratechnologies Inc. (OTCMKTS:THERF) Continues Gains

Theratechnologies Inc. (OTCMKTS:THERF)

Theratechnologies Inc. (OTCMKTS:THERF) is a specialty pharmaceutical company headquartered in Montreal, Canada. The biotechnology firm focuses on addressing the unmet medical needs of HIV patients and promotes healthy living and an improved quality of life among HIV patients. Theratechnologies works with TaiMed Biologics, Inc. and on May3, 2017, the two companies announced that a Biologics License Application (BLA) had been filed with the U.S. Food and Drug Administration (FDA) for ibalizumab for the treatment of multidrug resistant Human Immunodeficiency Virus-1 (MDR HIV-1). If approved, ibalizumab will be the first antiretroviral treatment (ART) with a new mechanism of action to be introduced in nearly ten years and the only treatment that does not require daily dosing.

Previously, Ibalizumab received a “Breakthrough Therapy” designation from the U.S. Food and Drug Administration. The Orphan Drug designation is given to a therapy, or treatment, if it represents an important improvement over existing options for life-threatening diseases or conditions. The FDA also granted Ibalizumab with an “Orphan Drug” designation. Drugs with the Orphan Drug designation are eligible for certain financial advantages during development and commercialization.

HIV is a particularly troublesome virus as it sometimes mutates and produces drug-resistant strains which means that previous, effective treatments will fail. The number of HIV afflicted Americans that are currently resistant to traditional treatments is said to number between 20,000 – 50,000. Of that number, 12,000 are estimated to have the virus mutate in the middle of treatment so that modification is required.

Theratechnologies Inc. (OTCMKTS:THERF) helped develop Ibalizumab for the treatment of HIV. The key characteristic of the drug is that it binds to the second extracellular domain of the CD$+ T cell receptor. This means, potentially, that Ibalizumab can prevent HIV from infecting CD+ immune cells while not affecting normal immunological function. In other words – Ibalizumab is active against HIV viruses that have been proved resistant to currently approved treatments.

In other news, Theratechnologies Inc. (OTCMKTS:THERF) announced the election of a new board member. Dale Weil has 35 years of business development experience – much of it in the healthcare sector. Most recently, Mr. Weil was a senior advisor to the President of McKesson Canada. McKesson Canada is a $33 Billion healthcare company involved in the delivery of pharmaceuticals, medical supplies, and information technology.

Theratechnologies Inc. (OTCMKTS:THERF) opened 2017 at $2.05 and has recently traded over $5.50 for a gain of over 175%. For comparative purposes, the S&P 500 has gained around 8%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $THERF and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Abeona Therapeutics Inc (NASDAQ:ABEO) Receives FDA Orphan Drug Designation

Abeona Therapeutics Inc (NASDAQ:ABEO) Receives FDA Orphan Drug Designation

Abeona Therapeutics Inc (NASDAQ:ABEO) has announced receiving an Orphan Drug Designation (ODD) from the U.S. Federal Drug Administration (FDA) for its EB-101 gene therapy targeting dystrophic epidermolysis bullosa (DEB) patients. This also includes recessive dystrophic epidermolysis bullosa (RDEB), a deadly genetic skin disorder characterized by lesions and skin blisters. Abeona specializes in the development of gene therapies for treatment of life-threatening diseases.

In a statement, Abeona Therapeutics Inc (NASDAQ:ABEO) President & CEO, Timothy J. Miller, Ph.D said Abeona’s main agenda is to develop therapies to address the huge unmet demands from patients suffering from dystrophic epidermolysis bullosa. He added that they highly grateful for the new designation and the recognition of EB-101 by FDA as a rare product which will offer much needed therapeutic benefits to patients suffering from dystrophic types of epidermolysis bullosa among them RDEB. EB-101 is the company’s third gene therapy to be given the Orphan Drug Designation by the FDA that, as Miller states, is an important driver to the company’s program as it offers seven years of therapies for the same indications.

Wounds that appear on patients with RDEB, referred to as “butterfly skin” syndrome, can go unhealed for several months or even years as a result of the inability of the skin to remain attached to the dermis below and can spread over a large part of the body. During the Phase 1/2 clinical study, EB-101 was used to treat non-healing chronic wounds on each patient and examined the process of healing at particular time intervals over years. The clinical trial’s endpoint examined the safety as well as evaluating the healing process and compared the results to control untreated wounds. The secondary endpoint of the trial includes collagen C7 as well as the restoration of anchoring fibrils after three and six months of post-treatment.

EB is a class of deadly genetic skin diseases which leads to growth of erosions and blisters on the skin and spreads over the entire body. The most deadly is the epidermolysis bullosa (RDEB), which is known for open and painful wounds, skin blistering, esophageal strictures, joint contractures, corneal abrasions, pseudosyndactyly and a shortened life span. Patients suffering from RDEB have a shortage of type VII collagen (C7) as a results of gene mutations in the gene COL7A1 which encodes for C7 and the main element of anchoring fibrils, which make the connection between the dermis and the epidermis.

Abeona Therapeutics Inc (NASDAQ:ABEO) closed Thursday’s session at $4.75 losing 4.04%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ABEO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Re-acquires Belbuca

BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has been on an upward trend after reporting Q1 2017 earnings that beat estimates. Reacquisition of license rights to pain the management product, Belbuca, continues to fuel investor’s sentiments on the stock.

Stellar Q1 Earnings

The pain management product remains a key driver of the company’s earnings. During the first quarter, the drug generated sales that propelled BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to profitability. First quarter net income came in at $48.3 million or $0.58 cents a share, blowing away analysts’ earnings expectations of $0.09 cents a share.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Chief Executive Officer, Mark Sirgo, expects revenue and earnings growth to continue into the second half of the year.

“We completed a swift and effective transition of BELBUCA following the early January close of the transaction with Endo Pharmaceuticals (Endo), and by the end of the quarter, we were generating sufficient product revenue to offset the expense of our commercial business unit. In fact, we recorded the highest net sales revenue for BELBUCA since the product was launched over a year ago…,” said Mr. Sirgo.

BioDelivery Sciences reported net revenues of $29.5 million for the first quarter, compared to net revenue of $3 million reported last year. Belbuca accounted for $4.6 million of total revenues. The company would have earned $640,000 in royalty payments from the drug had it not reacquired it. Cash and cash equivalent as of the end of the first quarter totaled $35.2 million compared to $32 million as of December 31, 2016.

Growth Drivers

The specialty pharmaceutical company is currently pursuing licensing agreements for Belbuca as it continues to pursue new sales avenues. The company is also eyeing approval in Canada to supplement sales in the U.S. Early this year the company secured $75 million in financing that it plans to use for the commercialization of the drug.

Belbuca is not the only product that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is relying on for revenues. Bunavail is the company’s other lead product and it generated revenues of $3.2 million in the quarter, up from $2.1 million as of last year.

“As for BUNAVAIL®, we will continue to focus our efforts on our current prescribers while working to secure new managed contracts where BUNAVAIL is in a favorable position. BUNAVAIL generated $3.2 million in revenue for the quarter,” said Mr. Sirgo.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) plans to make a regulatory submission later in the year for the manufacture of ONSOLIs, a drug it licensed to Collegium Pharmaceuticals in 2016

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) closed a $2.30 on volume of 213,882.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BDSI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

NewLink Genetics Corp (NASDAQ:NLNK) Plunges After Genentech Withdrawl

NewLink Genetics Corp (NASDAQ:NLNK)

NewLink Genetics Corp (NASDAQ:NLNK) stock plunged after the company announced the termination of a licensing agreement with Genentech for its IDO inhibitor, GDC-0919,. However, the termination will not affect research collaboration on the discovery of other IDO/TDO inhibitors between the two firms.

GDC-0919 Disappointing results

Genentech’s decision came as a surprise, given that data on the inhibitor was recently presented at the American Society of Clinical Oncology annual meeting. The two companies had signed the licensing agreement in 2014.

NewLink Genetics Corp (NASDAQ:NLNK) stock shed more than a third of its market value on Genentech ending its collaboration on GDC-0919 development. Disappointing clinical trial results appears to have triggered the surprise move by Genentech. The trial of GDC-0919 in combination with Roche’s –PD-L1 failed to yield the desired results.

Clinical Trial results indicate that the response rate for GDC-0919 stood at 9% in patients with solid tumor cancers. The response rate was quite low to justify further clinical research. Epacadostat, a drug being marketed by Incyte Corporation (NASDAQ:INCY), delivered a response rate of 30-35% when combined with Merck & Co., Inc. (NYSE:MRK) PD-L inhibitor.

Even on the disappointing results CEO, Charles Link, remains optimistic about GDC-0919 prospects.

“We are obviously disappointed in this decision. We remain committed to advancing our IDO pathway inhibitor indoximod, which continues to generate exciting data in combination with anti-PD-1 agents, cancer vaccines, and chemotherapy in multiple cancer types including melanoma, prostate cancer, acute myeloid leukemia, and pancreatic cancer,” said Mr. Link.

Genentech returning rights of GDC-0919 caps another setback on NewLink Genetics Corp (NASDAQ:NLNK)’s push to build out its pipeline of oncology drugs. Early this month the biopharmaceutical company announced that one of its IDO-inhibitors had failed in a mid-stage breast cancer trial. The negative results prevents the company from expanding its usage beyond melanoma treatment.

NewLink Genetics Corp (NASDAQ:NLNK) stock remains under pressure as a wave of negative results on the clinical trial front continues to spook investors. NewLink Genetics Corp (NASDAQ:NLNK) stock was up by 1.30% in Wednesday’s trading session, to end the day at $6.22 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NLNK and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Microbot Medical Inc (NASDAQ:MBOT) Announces Patent News

Microbot Medical Inc (NASDAQ:MBOT)

Microbot Medical Inc (NASDAQ:MBOT), headquartered in Massachusetts, shares are trading in heavy volumes on the back of a news release announcing that the company has been granted patent number 9,675,748 by the United States Patent and Trademark Office (USPTO). The patent was granted for Microbot’s device which aims to prevent shunt stenosis. Shunt systems are used in conjunction with catheters, including ventricular catheters, and are susceptible to complications. Shares of MBOT have jumped over 5% on the news to around $2.22 on volumes over 60 times their average.

Microbot Medical Inc (NASDAQ:MBOT), founded in 2010, became a NASDAQ listed company in November of 2016. The biotech device company specializes in transformational micro-robotic medical technologies. Microbot Medical Inc (NASDAQ:MBOT)’s current platforms, ViRob™ and TipCAT™, are comprised of two highly advanced micro-robotic technologies. Those technologies have enabled the development of two product candidates: the Self Cleaning Shunt™, or SCS™, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH. Also being developed is a self-propelling, semi-disposable endoscope for use in colonoscopy procedures.

Since its 2016 NASDAQ IPO, Microbot Medical Inc (NASDAQ:MBOT) shares have not enjoyed a honeymoon with investors. MBOT shares are down over 40% for the past year and down over 65% YTD. The last month has seen the majority of that loss as MBOT recorded a drop of over 50% in the last 30 days. Currently MBOT shares are sitting barely 15% over their 52-week lows of $1.95. That is quite a fall from their 52-week high of $26.91.

Harel Gadot, CEO, President and Chairman of Microbot Medical Inc (NASDAQ:MBOT), stated “Our innovative technology platforms, which we believe are well ahead of the micro robotic curve, position the Company to address multi-billion market opportunities. The addition of the proceeds from our recently completed equity offering gives us the resources to execute upon these opportunities and strengthen our unique core capabilities to implement other market-penetrating growth prospects”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. All information, or data, is provided with no guarantees of accuracy.

Don’t miss out! Stay informed on $MBOT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.